Study of MEDI 507 in the Treatment of Pediatric Patients (Pediatric GvHD)

This study has been completed.
Sponsor:
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00813618
First received: December 19, 2008
Last updated: NA
Last verified: December 2008
History: No changes posted

December 19, 2008
December 19, 2008
September 1999
June 2004   (final data collection date for primary outcome measure)
Safety assessment of escalating dose levels of MEDI-507 in pediatric stell scell (SCT) and bone marrow (BMT) allograft recipients who have at least Grade II Graft-versus-Host Disease (GvHD). [ Time Frame: Through Study Day 44 ] [ Designated as safety issue: Yes ]
Same as current
No Changes Posted
Evaluate the serum concentrations and pharmacokinetics (PK) of MEDI 507 and pharmacodynamic effects of MEDI-507 on the absolute lymphocyte count and dynamics of lymphocyte phenotypes. [ Time Frame: Through Study Day 364 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Study of MEDI 507 in the Treatment of Pediatric Patients
Phase I Study of MEDI 507 in the Treatment of Pediatric Patients With at Least Grade II Acute Graft-Versus-Host Disease (GvHD)

To assess the safety of escalating dose levels of MEDI-507 in pediatric stem cell and bone marrow allograft recipients who have at least Grade II GvHD.

This is a Phase I, open-label dose escalation trial of MEDI-507 in pediatric SCT and BMT recipients with at least Grade II acute GvHD. All patients will receive steroid therapy and MEDI-507 for treatment of GvHD

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Graft Versus Host Disease
  • Drug: MEDI-507
    0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
  • Drug: MEDI-507
    0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
  • Drug: MEDI-507
    0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
  • Experimental: 1
    MEDI-507
    Intervention: Drug: MEDI-507
  • Experimental: 2
    MEDI-507
    Intervention: Drug: MEDI-507
  • Experimental: 3
    MEDI-507
    Intervention: Drug: MEDI-507
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
August 2004
June 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Allogeneic BMT or SCT recipients
  • Acute GvHD of at least Grade II severity
  • Age 2 to 17 years
  • Evidence of engraftment (ANC over 500 cells/mm3 on two consecutive days within seven days before study entry)
  • Receipt of GvHD prophylaxis regimen including methotrexate, tacrolimus or cyclosporine
  • Receipt of at least 2 mg/kg of methylprednisolone (or equivalent corticosteroid) between eight and 24 hours prior to the first MEDI-507 dose for GvHD treatment
  • Both males and females are eligible, but sexually active females at risk of pregnancy of childbearing potential must agree to use an effective method of avoiding pregnancy (which includes oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) beginning 30 days before the first study infusion and continuing through 60 days after the final study infusion.

Exclusion Criteria:

  • Treatment of acute GvHD with methylprednisolone (or equivalent corticosteroid) at a total dose exceeding 14 mg/kg (or equivalent) over a seven day period (for example, 2 mg/kg/day for seven days)
  • Previous receipt of MEDI 507
  • Previous treatment with any anti-T cell monoclonal antibodies, such as OKT3, daclizumab (Zenapax), or basiliximab (Simulect)
  • Treatment with anti-thymocyte globulin (ATG, ATGAM or others) within 14 days
  • More than one allogeneic bone marrow or hematopoietic stem cell allograft
  • Use of other investigational agents within 30 days (this does not include the use of licensed agents for indications not listed in the package insert) or current participation in a research protocol in which an investigational agent was administered
  • Any of the following clinical settings or diagnoses:
  • documented or presumed significant active infection
  • pregnancy or nursing mother
  • evidence of infection with HIV-1, hepatitis B or C virus
  • hemodialysis or chronic peritoneal dialysis
  • use of a ventilator
  • chronic GvHD
  • active veno-occlusive disease of the liver
  • moribund patient
Both
2 Years to 17 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00813618
MI-CP049
No
Christine A. Dingivan, MD, Medimmune LLC
MedImmune LLC
Not Provided
Not Provided
MedImmune LLC
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP